Prescription THC reduces PTSD nightmares in over one-third of patients

A recent clinical study has found that a prescription form of tetrahydrocannabinol (THC) can significantly reduce trauma‑related nightmares in people with post‑traumatic stress disorder (PTSD). The research, which followed participants for ten weeks, reported that more than one‑third of those treated with the THC formulation experienced a complete disappearance of their nightmares. The findings were presented in a peer‑reviewed journal and suggest a potential new avenue for addressing one of PTSD’s most persistent and distressing symptoms.

The study enrolled a diverse group of adults diagnosed with PTSD who had chronic, recurring nightmares. Participants received a standardized dose of the prescription THC product under medical supervision, with regular monitoring of sleep patterns and symptom severity. In addition to the primary outcome of nightmare frequency, researchers also assessed overall sleep quality and PTSD symptom clusters, noting improvements across several domains. The results align with prior anecdotal reports that cannabinoids may modulate the neural circuits involved in nightmare generation.

If these findings are replicated in larger, multi‑center trials, the THC formulation could become a long‑awaited therapeutic option for patients whose nightmares remain refractory to existing pharmacologic and behavioral interventions. The study adds to a growing body of evidence that targeted cannabinoid therapy may address specific PTSD symptoms, offering clinicians and patients a new tool to improve sleep and reduce the burden of trauma‑related distress.